Glutamate and glycine co-activate while polyamines merely modulate the NMDA receptor complex.
1. Agonists may act at any one of three sites on the N-methyl-D-aspartate (NMDA) receptor-effector complex to promote opening of the associated ion channel. The three sites are activated by i) NMDA, L-glutamate, aspartate, and other dicarboxylic amino acids; ii) glycine, D-serine, D-cycloserine, and others; iii) the polyamines spermine or spermidine, but not cadaverine or putrescine. 2. This opening by exogenous agonists is reflected by an enhanced binding of the phencyclidine-like dissociative anesthetic [3H]MK-801 to rat cortical membranes (well washed to remove endogenous agonists, e.g., L-glutamate, glycine). 3. The effects of adding combinations of agonists yielded stimulation approximately equal to the sum of each agonist's effect, suggesting that in the first approximation the three classes act at independent sites. 4. When the glutamate (E) site was antagonized with D-2-amino-5-phosphonopentanoate (D-AP5), no stimulation in binding could be elicited by agonists at the two other sites. Activation of the E site is therefore necessary but not sufficient for channel opening. 5. When the glycine (G) site was antagonized with 7-chlorokynurenate, no stimulation in binding could be elicited by agonists at the other two sites. Activation of the G site is therefore necessary but not sufficient for channel opening. 6. Of the two putative antagonists for the polyamine (PA) site, ifenprodil fails to completely inhibit the binding of [3H]MK-801, whereas arcaine inhibited [3H]MK-801 binding completely. We present data which question the selectivity of arcaine for the polyamine site, and propose that the polyamine site is merely modulatory, but neither necessary nor sufficient, for channel opening.
Lehmann
J
J
Fondax-Groupe de Recherche Servier, Puteaux, France.
Colpaert
F
F
Canton
H
H
D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001645:Biguanides / Q000494:pharmacology; D001667:Binding, Competitive / Q000187:drug effects; D015317:Biogenic Polyamines / Q000502:physiology*; D001711:Biotransformation / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D016291:Dizocilpine Maleate / Q000378:metabolism; D005971:Glutamates / Q000378:metabolism* / Q000502:physiology; D018698:Glutamic Acid; D005998:Glycine / Q000378:metabolism* / Q000502:physiology; D066298:In Vitro Techniques; D007736:Kynurenic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000502:physiology*; D013095:Spermidine / Q000494:pharmacology; D013096:Spermine / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D001645:Biguanides; D015317:Biogenic Polyamines; D005971:Glutamates; D010880:Piperidines; D016194:Receptors, N-Methyl-D-Aspartate; D013096:Spermine; D018698:Glutamic Acid; C006624:arcaine; D016291:Dizocilpine Maleate; D015763:2-Amino-5-phosphonovalerate; D007736:Kynurenic Acid; C010739:ifenprodil; C057013:7-chlorokynurenic acid; D005998:Glycine; D013095:Spermidine